HIV French Resistance - HIV-1 genotypic drug resistance interpretation’s algorithms
Title: HIV French Resistance - HIV-1 genotypic drug resistance interpretation’s algorithms
Keywords: HIV, genotype, resistance, AC11, mutations, algorithm, antiretroviral, NRTI, NNRTI, PI
Description: HIV-1 genotypic drug resistance interpretation’s algorithms is ranked 19384111 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $5,736. This site has a low Pagerank(0/10). It has 1 backlinks. has 43% seo score. Information

Website / Domain:
Website IP Address:
Domain DNS Server:, Rank

Alexa Rank: 19384111
Google Page Rank: 0/10 (Google Pagerank Has Been Closed) Traffic & Earnings

Purchase/Sale Value: $5,736
Daily Revenue: $15
Monthly Revenue $471
Yearly Revenue: $5,736
Daily Unique Visitors 1,446
Monthly Unique Visitors: 43,380
Yearly Unique Visitors: 527,790 WebSite Httpheader

StatusCode 200
Content-Type text/html
Date Tue, 02 Aug 2016 23:54:43 GMT
Server Apache Keywords accounting

Keyword Count Percentage
HIV 17 2.31%
genotype 0 0.00%
resistance 15 7.10%
AC11 2 0.35%
mutations 3 1.21%
algorithm 3 1.21%
antiretroviral 5 3.19%
NRTI 0 0.00%
NNRTI 0 0.00%
PI 11 0.98% Traffic Sources Chart Similar Website

Domain Site Title Alexa Rank History Chart aleax Html To Plain Text

HIV French Resistance - HIV-1 genotypic drug resistance interpretation’s algorithms Home Board Tables of Rules HIV tropism Archives HIV-1 RT and protease sequencing and drug susceptibility testing have been done in research settings for more than ten years to elucidate the genetic mechanisms of resistance to antiretroviral drugs. The accumulation of retrospective and prospective data has led expert panels to recommend the use of resistance testing in the decision of treatment of HIV-infected patients. The French ANRS (National Agency for AIDS Research) AC11 Resistance group provides HIV-1 genotypic drug resistance interpretation’s algorithms in order to guide physicians in the choice of antiretroviral treatment.These algorithms are mainly based on correlation between drug resistance mutations and virological outcome from patients failing antiretroviral therapy. The rules are presented as tables listing mutations conferring genotypic resistance or possible genotypic resistance to anti-HIV drugs and will be updated regularly. . January 2015 HIV-1 PCR and Sequencing Procedures . September 2015 Last tables of rules HIV-1(V25) Last tables of rules HIV-2(V25) NGS procedure HIV-1 subtyping Greg+, a molecular biology tool for mutation detection, analysis and interpretation RECOMMANDATIONS OF THE ANRS AC11 RESISTANCE GROUP HIV drug-resistance testing in plasma is recommended in persons with HIV infection at entry into care regardless of whether antiretroviral therapy (ART) will be initiated immediately or deferred. Genotypic testing in plasma is recommended as the preferred resistance testing to guide therapy in antiretroviral (ARV)-naive patients. Standard genotypic drug-resistance testing in plasma in ARV-naive persons involves testing for mutations in the reverse transcriptase (RT), protease (PR) and integrase (IN) genes. HIV drug-resistance testing in plasma should be performed to assist in the selection of active drugs when changing ARV regimens in persons with virologic failure (confirmed plasma HIV RNA >50 copies/mL). In persons with plasma HIV RNA >50 but 50 copies/mL in CSF of a patient treated by ARV, genotypic resistance testing should be performed on the CSF. ARV drug level measurements should be also performed in CSF. Whois

Domain ID: D93852423-LROR
WHOIS Server:
Referral URL:
Updated Date: 2016-01-10T16:20:04Z
Creation Date: 2003-01-10T11:08:56Z
Registry Expiry Date: 2017-01-10T11:08:56Z
Sponsoring Registrar: eNom, Inc.
Sponsoring Registrar IANA ID: 48
Domain Status: clientTransferProhibited
Registrant ID: VC1630-BR
Registrant Name: Vincent Calvez
Registrant Organization: Htpital Pitii-Salpjtrihre
Registrant Street: 83 Boulevard de l'htpital
Registrant City: Paris
Registrant State/Province: N/A
Registrant Postal Code: 75013
Registrant Country: FR
Registrant Phone: +3.3142177401
Registrant Phone Ext:
Registrant Fax: +3.3142177411
Registrant Fax Ext:
Registrant Email:
Admin ID: BD808-BR
Admin Name: Domain Manager Siteparc
Admin Organization: SITEPARC
Admin Street: 125 rue Aristide Briand
Admin State/Province: N/A
Admin Postal Code: 92300
Admin Country: FR
Admin Phone: +3.3147318541
Admin Phone Ext:
Admin Fax:
Admin Fax Ext:
Admin Email:
Tech ID: BD808-BR
Tech Name: Domain Manager Siteparc
Tech Organization: SITEPARC
Tech Street: 125 rue Aristide Briand
Tech State/Province: N/A
Tech Postal Code: 92300
Tech Country: FR
Tech Phone: +3.3147318541
Tech Phone Ext:
Tech Fax:
Tech Fax Ext:
Tech Email:
DNSSEC: unsigned
>>> Last update of WHOIS database: 2016-09-30T16:11:49Z <<<
For more information on Whois status codes, please visit
Access to Public Interest Registry WHOIS information is provided to assist persons in determining the contents of a domain name registration record in the Public Interest Registry registry database. The data in this record is provided by Public Interest Registry for informational purposes only, and Public Interest Registry does not guarantee its accuracy. This service is intended only for query-based access. You agree that you will use this data only for lawful purposes and that, under no circumstances will you use this data to(a) allow, enable, or otherwise support the transmission by e-mail, telephone, or facsimile of mass unsolicited, commercial advertising or solicitations to entities other than the data recipient's own existing customers; or (b) enable high volume, automated, electronic processes that send queries or data to the systems of Registry Operator, a Registrar, or Afilias except as reasonably necessary to register domain names or modify existing registrations. All rights reserved. Public Interest Registry reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy